SPIMACO’s net profit rises 62% to SAR 366 mln in nine-months 2015

SPIMACO’s net profit rises 62% to SAR 366 mln in nine-months 2015

19/10/2015 Argaam Exclusive

View other reports

 

Saudi Pharmaceutical Industries & Medical Appliances Corp. (SPIMACO) reported a net profit of SAR 366.2 million for the first nine months of 2015, a 62.3 percent increase compared to the same period last year mainly attributed to sales growth and the sale of its stake in EirGen Pharma to Opko.



Financials (M)

Item 9m 2014 9m 2015 Change‬
Revenues 1,042.37 1,176.27 12.8 %
Gross Income 534.32 568.12 6.3 %
Operating Income 152.22 164.06 7.8 %
Net Income 225.57 366.17 62.3 %
Average Shares 120.00 120.00 -
EPS (Riyals) 1.88 3.05 62.3 %

 

The company reported a net income of SAR 29.2 million in Q3 this year, a 20.4 percent decline year-on-year on higher expenses and lower dividends from the company’s investments.



Current Quarter Comparison (M)

Compared With The
Item Q3 2014 Q3 2015 Change‬
Revenues 266.02 308.27 15.9 %
Gross Income 134.45 131.32 (2.3 %)
Operating Income 31.26 24.69 (21.0 %)
Net Income 36.69 29.16 (20.5 %)
Average Shares 120.00 120.00 -
EPS (Riyals) 0.31 0.24 (20.5 %)


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2006 194.37 17.1 % 91.95 23.6 % 37.75 9.3 %
Q2 2006 185.74 21.6 % 71.43 19.9 % 24.97 22.8 %
Q3 2006 156.57 10.9 % 64.50 9.4 % 23.63 7.4 %
Q4 2006 191.16 1.1 % 80.54 3.1 % 21.73 (13.1 %)
Q1 2007 203.37 4.6 % 91.01 (1.0 %) 40.00 6.0 %
Q2 2007 209.28 12.7 % 66.46 (7.0 %) 3.13 (87.5 %)
Q3 2007 149.40 (4.6 %) 66.84 3.6 % 24.13 2.1 %
Q4 2007 235.70 23.3 % 102.31 27.0 % 30.48 40.3 %
Q1 2008 220.58 8.5 % 99.57 9.4 % 41.61 4.0 %
Q2 2008 211.66 1.1 % 74.78 12.5 % 11.06 253.2 %
Q3 2008 145.45 (2.6 %) 74.34 11.2 % 21.36 (11.5 %)
Q4 2008 294.26 24.8 % 114.28 11.7 % 38.48 26.3 %
Q1 2009 257.88 16.9 % 108.57 9.0 % 46.06 10.7 %
Q2 2009 229.00 8.2 % 81.53 9.0 % 16.76 51.6 %
Q3 2009 171.15 17.7 % 72.49 (2.5 %) 18.81 (11.9 %)
Q4 2009 292.71 (0.5 %) 157.00 37.4 % 64.46 67.5 %
Q1 2010 274.33 6.4 % 118.90 9.5 % 52.94 14.9 %
Q2 2010 252.34 10.2 % 100.50 23.3 % 21.50 28.3 %
Q3 2010 191.40 11.8 % 85.88 18.5 % 20.68 9.9 %
Q4 2010 319.57 9.2 % 181.12 15.4 % 70.70 9.7 %
Q1 2011 252.08 (8.1 %) 123.51 3.9 % 49.79 (6.0 %)
Q2 2011 292.08 15.7 % 123.61 23.0 % 30.59 42.3 %
Q3 2011 209.24 9.3 % 106.76 24.3 % 33.19 60.5 %
Q4 2011 375.82 17.6 % 206.69 14.1 % 76.86 8.7 %
Q1 2012 303.14 20.3 % 153.21 24.0 % 63.10 26.7 %
Q2 2012 286.64 (1.9 %) 140.91 14.0 % 34.78 13.7 %
Q3 2012 227.40 8.7 % 113.28 6.1 % 39.61 19.3 %
Q4 2012 365.97 (2.6 %) 211.16 2.2 % 63.57 (17.3 %)
Q1 2013 361.37 19.2 % 184.62 20.5 % 70.64 11.9 %
Q2 2013 344.22 20.1 % 179.12 27.1 % 40.64 16.8 %
Q3 2013 222.91 (2.0 %) 118.64 4.7 % 35.37 (10.7 %)
Q4 2013 382.01 4.4 % 226.14 7.1 % 60.19 (5.3 %)
Q1 2014 405.21 12.1 % 206.72 12.0 % 76.05 7.7 %
Q2 2014 371.14 7.8 % 193.14 7.8 % 44.90 10.5 %
Q3 2014 266.02 19.3 % 134.45 13.3 % 31.26 (11.6 %)
Q4 2014 431.06 12.8 % 261.80 15.8 % 90.22 49.9 %
Q1 2015 432.20 6.7 % 225.86 9.3 % 91.35 20.1 %
Q2 2015 435.80 17.4 % 210.95 9.2 % 48.02 6.9 %
Q3 2015 308.27 15.9 % 131.32 (2.3 %) 24.69 (21.0 %)


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
Q1 2006 37.65 6.4 % 0.37 - 37.65 0.37
Q2 2006 19.13 (21.2 %) 0.19 - 19.13 0.19
Q3 2006 23.80 15.1 % 0.23 - 23.80 0.23
Q4 2006 24.46 54.8 % 0.24 - 24.46 0.24
Q1 2007 39.50 4.9 % 0.39 - 39.50 0.39
Q2 2007 22.57 18.0 % 0.22 - 22.57 0.22
Q3 2007 26.53 11.4 % 0.26 - 26.53 0.26
Q4 2007 33.28 36.1 % 0.33 - 33.28 0.33
Q1 2008 40.93 3.6 % 0.40 - 40.93 0.40
Q2 2008 34.24 51.7 % 0.34 (0.45) 34.70 0.34
Q3 2008 15.62 (41.1 %) 0.15 (3.69) 19.83 0.20
Q4 2008 37.48 12.6 % 0.37 - 37.48 0.37
Q1 2009 42.69 4.3 % 0.42 (0.18) 42.87 0.42
Q2 2009 37.81 10.4 % 0.37 0.00 37.81 0.37
Q3 2009 15.84 1.4 % 0.16 0.00 15.84 0.16
Q4 2009 58.48 56.0 % 0.58 (3.12) 61.60 0.61
Q1 2010 45.32 6.2 % 0.38 (3.24) 48.56 0.40
Q2 2010 43.09 14.0 % 0.36 - 43.09 0.36
Q3 2010 18.07 14.1 % 0.15 - 18.07 0.15
Q4 2010 70.04 19.8 % 0.58 - 70.04 0.58
Q1 2011 45.71 0.9 % 0.38 - 45.71 0.38
Q2 2011 60.75 41.0 % 0.51 - 60.75 0.51
Q3 2011 29.75 64.6 % 0.25 - 29.75 0.25
Q4 2011 74.06 5.7 % 0.62 - 74.06 0.62
Q1 2012 56.45 23.5 % 0.47 - 56.45 0.47
Q2 2012 90.14 48.4 % 0.75 - 90.14 0.75
Q3 2012 32.33 8.7 % 0.27 - 32.33 0.27
Q4 2012 53.73 (27.5 %) 0.45 - 53.73 0.45
Q1 2013 63.15 11.9 % 0.53 - 63.15 0.53
Q2 2013 113.71 26.1 % 0.95 - 113.71 0.95
Q3 2013 34.19 5.8 % 0.28 - 34.19 0.28
Q4 2013 57.01 6.1 % 0.48 - 57.01 0.48
Q1 2014 91.17 44.4 % 0.76 - 91.17 0.76
Q2 2014 97.72 (14.1 %) 0.81 - 97.72 0.81
Q3 2014 36.69 7.3 % 0.31 - 36.69 0.31
Q4 2014 91.29 60.1 % 0.76 - 91.29 0.76
Q1 2015 99.39 9.0 % 0.83 - 99.39 0.83
Q2 2015 237.63 143.2 % 1.98 151.31 86.32 0.72
Q3 2015 29.16 (20.5 %) 0.24 - 29.16 0.24

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2006 42.61 % 18.61 % 14.53 %
Q2 2006 42.30 % 18.33 % 13.13 %
Q3 2006 42.16 % 18.23 % 13.28 %
Q4 2006 42.37 % 17.65 % 14.43 %
Q1 2007 41.73 % 17.98 % 14.51 %
Q2 2007 39.78 % 14.82 % 14.51 %
Q3 2007 40.47 % 15.48 % 15.01 %
Q4 2007 40.94 % 15.79 % 15.28 %
Q1 2008 41.13 % 15.70 % 15.13 %
Q2 2008 42.03 % 16.67 % 16.57 %
Q3 2008 43.15 % 16.47 % 15.83 %
Q4 2008 41.63 % 16.30 % 15.25 %
Q1 2009 40.91 % 16.13 % 14.83 %
Q2 2009 40.87 % 16.44 % 14.89 %
Q3 2009 39.57 % 15.73 % 14.07 %
Q4 2009 44.13 % 18.49 % 16.63 %
Q1 2010 44.45 % 18.88 % 16.94 %
Q2 2010 45.32 % 18.93 % 17.07 %
Q3 2010 45.73 % 18.73 % 16.95 %
Q4 2010 46.88 % 18.85 % 17.32 %
Q1 2011 48.36 % 18.99 % 17.42 %
Q2 2011 48.73 % 19.12 % 18.44 %
Q3 2011 49.86 % 19.99 % 19.22 %
Q4 2011 49.64 % 19.57 % 18.62 %
Q1 2012 50.01 % 19.86 % 18.73 %
Q2 2012 51.72 % 20.36 % 21.31 %
Q3 2012 51.47 % 20.54 % 21.21 %
Q4 2012 52.28 % 19.56 % 19.66 %
Q1 2013 52.36 % 19.26 % 19.28 %
Q2 2013 52.98 % 18.87 % 20.24 %
Q3 2013 53.58 % 18.66 % 20.45 %
Q4 2013 54.06 % 18.26 % 20.45 %
Q1 2014 53.95 % 17.92 % 21.86 %
Q2 2014 53.91 % 17.74 % 20.28 %
Q3 2014 53.39 % 16.79 % 19.84 %
Q4 2014 54.03 % 18.15 % 21.50 %
Q1 2015 54.34 % 18.90 % 21.67 %
Q2 2015 53.23 % 18.31 % 20.04 %
Q3 2015 51.63 % 17.40 % 19.05 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2006 101.51 0.97 0.97 25.43
Q2 2006 101.51 0.92 0.92 21.37
Q3 2006 101.51 0.95 0.95 27.26
Q4 2006 101.51 1.03 1.03 19.65
Q1 2007 101.51 1.05 1.05 19.84
Q2 2007 101.51 1.09 1.09 19.42
Q3 2007 101.51 1.11 1.11 21.04
Q4 2007 101.51 1.20 1.20 28.41
Q1 2008 101.51 1.21 1.21 26.83
Q2 2008 101.51 1.33 1.33 27.74
Q3 2008 101.51 1.22 1.27 21.88
Q4 2008 101.51 1.26 1.31 13.76
Q1 2009 101.51 1.28 1.33 14.17
Q2 2009 101.51 1.32 1.36 17.62
Q3 2009 101.51 1.32 1.32 19.72
Q4 2009 101.51 1.53 1.56 21.46
Q1 2010 120.00 1.31 1.36 22.04
Q2 2010 120.00 1.36 1.41 19.98
Q3 2010 120.00 1.37 1.43 21.69
Q4 2010 120.00 1.47 1.50 24.48
Q1 2011 120.00 1.47 1.47 25.41
Q2 2011 120.00 1.62 1.62 27.29
Q3 2011 120.00 1.72 1.72 25.92
Q4 2011 120.00 1.75 1.75 26.50
Q1 2012 120.00 1.84 1.84 30.26
Q2 2012 120.00 2.09 2.09 25.75
Q3 2012 120.00 2.11 2.11 26.24
Q4 2012 120.00 1.94 1.94 25.28
Q1 2013 120.00 1.99 1.99 27.18
Q2 2013 120.00 2.19 2.19 26.14
Q3 2013 120.00 2.21 2.21 27.35
Q4 2013 120.00 2.23 2.23 32.18
Q1 2014 120.00 2.47 2.47 32.96
Q2 2014 120.00 2.33 2.33 33.21
Q3 2014 120.00 2.35 2.35 35.74
Q4 2014 120.00 2.64 2.64 28.75
Q1 2015 120.00 2.71 2.71 27.84
Q2 2015 120.00 3.87 2.61 28.72
Q3 2015 120.00 3.81 2.55 24.87

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2006 More than 100 More than 100 4.07
Q2 2006 97.11 97.11 4.18
Q3 2006 89.06 89.06 3.10
Q4 2006 33.13 33.13 1.74
Q1 2007 30.19 30.19 1.60
Q2 2007 28.33 28.33 1.59
Q3 2007 28.70 28.70 1.52
Q4 2007 33.83 33.83 1.43
Q1 2008 27.68 27.68 1.25
Q2 2008 26.79 26.70 1.28
Q3 2008 20.49 19.74 1.14
Q4 2008 12.99 12.53 1.19
Q1 2009 14.92 14.39 1.35
Q2 2009 17.20 16.65 1.28
Q3 2009 18.29 18.26 1.22
Q4 2009 15.25 14.94 1.08
Q1 2010 16.69 16.04 0.99
Q2 2010 14.70 14.15 1.00
Q3 2010 14.64 14.10 0.93
Q4 2010 15.82 15.53 0.95
Q1 2011 17.65 17.65 1.02
Q2 2011 15.68 15.68 0.93
Q3 2011 14.41 14.41 0.96
Q4 2011 15.03 15.03 0.99
Q1 2012 17.92 17.92 1.09
Q2 2012 12.56 12.56 1.02
Q3 2012 13.70 13.70 1.10
Q4 2012 14.74 14.74 1.13
Q1 2013 13.60 13.60 1.00
Q2 2013 15.51 15.51 1.30
Q3 2013 15.70 15.70 1.27
Q4 2013 19.02 19.02 1.32
Q1 2014 19.07 19.07 1.43
Q2 2014 19.29 19.29 1.36
Q3 2014 21.41 21.41 1.41
Q4 2014 12.89 12.89 1.18
Q1 2015 14.78 14.78 1.44
Q2 2015 11.59 17.18 1.56
Q3 2015 9.46 14.14 1.45

Business Segments (Million)

Compared With The
Period Medical & Pharmaceutical production segment Investment activity
Q1 2006 194.37 -
Q2 2006 185.74 -
Q3 2006 156.57 -
Q4 2006 191.16 -
Q1 2007 203.37 -
Q2 2007 209.28 -
Q3 2007 149.40 -
Q4 2007 235.69 -
Q1 2008 220.58 -
Q2 2008 211.66 -
Q3 2008 145.45 -
Q4 2008 294.25 -
Q1 2009 257.88 -
Q2 2009 229.00 -
Q3 2009 171.15 -
Q4 2009 292.71 -
Q1 2010 274.33 -
Q2 2010 252.34 -
Q3 2010 191.41 -
Q4 2010 319.57 -
Q1 2011 252.08 -
Q2 2011 292.08 -
Q3 2011 209.24 -
Q4 2011 375.82 -
Q1 2012 303.14 -
Q2 2012 286.65 -
Q3 2012 227.40 -
Q4 2012 365.97 -
Q1 2013 361.37 -
Q2 2013 344.22 -
Q3 2013 222.91 -
Q4 2013 382.01 -
Q1 2014 405.21 -
Q2 2014 374.14 -
Q3 2014 266.02 -
Q4 2014 427.82 -
Q1 2015 432.29 14.84
Q2 2015 436.99 195.93
Q3 2015 308.38 9.55

Analysts Estimates (Million)

Item Q3 2015 (e) Q3 2015 (a) Change‬
Average 51.00 29.16 (42.8 %)

Estimates vs Actual (Million)

Item Q3 2015 (e) Q3 2015 (a) Change
99Hlala Capital 51.00 29.16 (42.8) %


Financial Ratios
Current
Market Cap (M Riyal) 3,804.00
Enterprise Value (EV) (M) 5,073.60
Shares Outstanding ((M)) 120.00
EPS ( Riyal) (TTM) 0.10
Book Value (BV) ( Riyal) 12.27
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) More than 100
P/E (TTM) More than 100
Price/book 2.58
Return on Average Assets (%) (TTM) 0.3
Return on Average Equity (%) (TTM) 0.8
more

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp.
31.70
0.25 0.79 %

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

More

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.